LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham

Key Points

• Regulatory and funding runway: LB Pharmaceuticals says FDA discussions support a streamlined path to approval in schizophrenia with a single Phase 3, the Phase 3 is underway with topline data expected in the second half of 2027, and the February PIPE funds the company through the second quarter of 2029, including NDA-enabling work and a 52-week safety extension.
• Drug design and positioning: LB-102 is a methylated derivative of amisulpride engineered for better brain penetration and once-daily low-dose dosing (50 mg roughly equivalent to 400 mg amisulpride by receptor occupancy) and is positioned to differentiate on cognition, anhedonia, and tolerability versus other antipsychotics.
• Clinical results: A 359-patient Phase 2 schizophrenia trial showed statistically significant PANSS improvements and dose-dependent cognitive benefits, with a favorable tolerability profile (low EPS, minimal prolactin and QT issues) supporting advancement to Phase 3.

LB Pharmaceuticals NASDAQ: LBRX is seeking to build a “fully integrated company focused on CNS-related diseases,” Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia.

Turner said the company’s lead program, LB-102, is a late-stage asset being developed in schizophrenia, bipolar depression, and adjunctive major depressive disorder (MDD). Based on discussions with the U.S. Food and Drug Administration following a Phase 2 schizophrenia study, Turner said the company believes there is a “streamlined path to approval in schizophrenia with just a single Phase III clinical trial.”

Funding runway and development timeline

Turner said the company’s February PIPE financing left it with a balance sheet that “takes us all the way through the clinical readouts and into the second quarter of 2029.” She added that the company is funded for its Phase 3 schizophrenia trial and associated NDA-enabling work, including an open-label safety study intended to build the safety database needed for a submission.

LB Pharmaceuticals outlined the following clinical timelines for LB-102:

• Schizophrenia: Phase 3 trial initiated; top-line data expected in the second half of 2027. The study will test 50 mg and 100 mg doses in about 460 inpatients over six weeks, with PANSS change from baseline at day 42 as the primary endpoint and cognition as a secondary endpoint.
• Open-label safety extension: Planned 52-week study targeting about 900 patients, including rollovers from the Phase 3 trial plus newly enrolled patients, to support safety exposure for an approval submission; the company also plans subset analyses for cognition and negative symptoms in stabilized outpatients.
• Bipolar depression: Phase 2 trial initiated; data expected in the first quarter of 2028. The six-week monotherapy trial targets 320 patients at 30 U.S. sites, using MADRS-10 as the primary endpoint and including secondary measures for cognition and anhedonia.
• Adjunctive MDD: Phase 2 trial expected to start in early 2027 with data in the first half of 2029. The six-week trial will enroll about 380 patients across the U.S. and EU and will evaluate LB-102 alongside an SSRI or SNRI, with MADRS-10 as the primary endpoint and prospective measures for anhedonia and cognition.

LB-102 design and mechanism: a derivative of amisulpride

Turner described LB-102 as a derivative of amisulpride, a generic antipsychotic used outside the U.S. that she said had more than 2 million prescriptions in 2023 “in a small subset of Europe.” According to Turner, amisulpride is selective for D2, D3, and 5-HT7 receptors, with relatively limited activity elsewhere, and is viewed as having a favorable safety-efficacy profile—but it has “very poor” blood-brain barrier penetration that drives higher dosing and twice-daily administration in schizophrenia.

LB Pharmaceuticals, Turner said, modified amisulpride via methylation to improve lipophilicity and brain exposure, enabling once-daily dosing at lower milligram doses with reduced systemic exposure. She said 50 mg of LB-102 is “about the same as 400 milligrams of amisulpride” based on dopamine receptor occupancy data, with both around 70% occupancy at those doses.

In the Q&A, Turner argued LB-102 differs from many antipsychotics because it is “not a promiscuous molecule” and because at lower doses it preferentially engages presynaptic autoreceptors, which she said can trigger dopamine release and may support potential effects in depression, anhedonia, and cognition.

Phase 2 schizophrenia results: efficacy, cognition, and tolerability

Turner highlighted results from a 4-week inpatient Phase 2 schizophrenia trial that studied 50 mg, 75 mg, and 100 mg doses in 359 patients across 25 U.S. sites. The primary endpoint was change from baseline at day 28, and the study also evaluated cognition using Cogstate.

Turner said each dose achieved “highly statistically superior” results versus placebo and produced a “clinically meaningful reduction” in PANSS score. She also said benefits appeared by the first week of evaluation and were sustained throughout the trial. Turner attributed the placebo performance in part to measures such as using a vendor to identify “professional patients,” central rater quality control, limiting scale burden to reduce fatigue, and close oversight of sites and the CRO.

On cognition, Turner said the trial showed a “robust dose-dependent effect” that was statistically significant versus placebo at each dose, citing a treatment effect of 0.66 at 100 mg. She also noted the company presented an additional analysis indicating the cognition benefit was driven by the drug rather than being a secondary consequence of treating positive symptoms.

On safety, Turner said discontinuations due to adverse events were low and the overall discontinuation rate was 27%, which she described as “on the lower side” for schizophrenia trials. She highlighted a low rate of extrapyramidal symptoms (EPS) of 1% to 5.6%, noting that at 100 mg the observed EPS rate was lower than placebo. Turner also cited low reported rates of adverse events associated with increased prolactin (1% to 5.6%), one case of sedation among 251 treated patients, and “minimal” QT prolongation with no patient meeting pre-specified stopping criteria.

Positioning versus muscarinic entrants and label considerations

Asked about competition from muscarinic antipsychotics, including Cobenfy, Turner pointed to challenges she said are associated with that class, including twice-daily dosing, a food effect requiring dosing on an empty stomach, and gastrointestinal and anticholinergic side effects that can lead to “suboptimally dosed” use in practice. Turner also cited switching considerations from commonly used generics and said LB-102’s once-daily dosing, lack of titration, and rapid onset of response could be competitive factors, alongside potential differentiation in cognition and anhedonia.

On the regulatory path for cognition and negative symptoms, Turner said FDA has been clear that, in schizophrenia, on-label claims for negative symptoms and cognition require studies in stabilized patients to avoid confounding from improvements in positive symptoms. In mood disorders, she pointed to the example of Trintellix and said cognition information may be able to appear in the “clinical trials section” of labeling if data are robust, while adding that publications may also influence physician decision-making.

Turner also said the company expects to include both 50 mg and 100 mg doses in the schizophrenia Phase 3 program with an intention to have both available, describing a potential role for higher dosing to stabilize patients and lower dosing for maintenance, similar to how she said amisulpride is used.

About LB Pharmaceuticals NASDAQ: LBRX

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.